Neuroscience

#Antibody #Antivirals #Immunology / Virology & Vaccines #Neurodegenerative disorders #Neuroscience #Oncology

This week in drug discovery (14-18 August)  

News round-up for 14-18 August by DDW Digital Content Editor Diana Spencer. My chosen news stories this week all discuss pre-clinical research studies that could have a huge impact on our therapeutic approach to several hard-to-treat diseases, helping to overcome drug-resistance and make treatments more targeted… Read More

#News

Dementia
#Alzheimer's #Dementia #Inherited tauopathies #Neurodegenerative disorders #Neuroscience #Oligomerix

Preclinical data supports new approach to Alzheimer’s disease

Preclinical data has demonstrated that the oral small molecule OLX-07010 inhibits tau aggregation in a model for inherited tauopathies such as progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD). Earlier this year, the company Oligomerix announced the first-in-human dosing of OLX-07010 in a Phase Ia clinical… Read More

#Editor's Choice #News

Human neurone
#Artificial intelligence (AI) #Francis Crick Institute #Neurodegenerative disorders #Neurology #Parkinson's #Personalised medicine

AI Parkinson’s discovery paves way for personalised treatments

A new study has demonstrated that machine learning can accurately predict subtypes of Parkinson’s disease using images of patient-derived stem cells, paving the way for personalised medicine and targeted drug discovery. The work, by the Francis Crick Institute, UCL Queen Square Institute of Neurology, and technology… Read More

#News #Trending News

Patient speaking to psychiatrist
#FDA #Mental health #Postpartum depression #Sage Therapeutics

First oral drug for postpartum depression approved in US

The US Food and Drug Administration (FDA) has approved Sage Therapeutics’ Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adults. Until now, treatment for PPD was only available as an IV injection given by a health care provider in certain health care facilities. “Postpartum depression… Read More

#News #Regulatory

Microscopic image of brain organoids tissue
#Human disease models #Neurodegenerative disorders #Neurology #Organoids #University of Michigan

Researchers create human brain organoids without animal cells

Researchers at University of Michigan (U-M) have developed a method to produce human brain organoids without animal cells that could improve the way neurodegenerative conditions are studied and treated. Human brain organoids are derived from embryonic or pluripotent stem cells and more closely model the complex… Read More

#News

Neuroblastoma
#Cancer research #Monoclonal antibodies #Neuroscience #Oncology #Phase II trial #Renaissance Pharma

Renaissance Pharma licenses Hu14.18 for neuroblastoma

Renaissance Pharma has announced its first development programme focused on Hu14.18, a humanised anti-GD2 monoclonal antibody (mAb), licensed from St Jude Children’s Research Hospital for the treatment of newly diagnosed high-risk neuroblastoma. Fifty percent of neuroblastoma patients have high-risk (HRNB) disease which has an overall survival… Read More

#Cancer Research #News

Biogen head office
#ALS #Alzheimer's #Biogen #Business #Investment #Mergers and acquisitions

Biogen acquires Reata and cuts 1,000 jobs

Biogen has revealed an agreement to acquire Reata Pharmaceuticals for approximately $7.3 billion. The news follows an announcement by the company last week that it would cut around 1,000 jobs, or 11% of its workforce, to allow investment into its product pipeline. In its second quarter results, the company said… Read More

#Business & Investment #News #Trending News

#Biomedical research #Clinical trials #Laboratory data #Long Covid #Neuroscience #Oncology #Trial data

New DDW Highlights episode now available

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The most impactful drug discovery news this week is all linked with scientific research… Read More

#News

#Biomedical research #Clinical trials #Laboratory data #Long Covid #Neuroscience #Oncology #Trial data

This week in drug discovery (17-21 July)  

News round-up for 17-21 July by DDW Digital Content Editor Diana Spencer. The most impactful drug discovery news this week is all linked with scientific research data. Analysts Phesi revealed that a third of clinical development programmes are cancelled during Phase II, and there were significant… Read More

#News

Scientific papers
#Academic #Data management #Neuroscience #Stanford University

Stanford president quits following false data accusations

The president of Stanford University in the US has announced he will resign after the university found that scientific papers he had published contained manipulated research data. The scientific misconduct inquiry did not find neuroscientist Marc Tessier-Lavigne guilty of falsifying research personally, but said that papers… Read More

#News #Trending News

Alzheimer's disease
#Alzheimer's #Clinical trials #Eli Lilly #Neuroscience

Donanemab significantly slowed decline in early Alzheimer’s disease trial 

Eli Lilly has announced positive results of the TRAILBLAZER-ALZ 2 Phase III study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease.   Donanemab met the primary endpoint of change from baseline until 18 months on the integrated Alzheimer’s Disease… Read More

#News #Trending News

Tau proteins
#Alzheimer's #Collaboration #Neurodegenerative disorders #Neuroscience #Tau protein

Collaborators pursue anti-tau therapy for neurodegeneration

IRBM, Rainwater Charitable Foundation and Weill Cornell Medicine will start of a multi-year drug discovery collaboration to identify small molecule cGAS (cyclic GMP-AMP synthase) inhibitors for the treatment of tauopathies and other neurodegenerative diseases. The collaboration brings together IRBM’s capabilities in drug discovery and development, RCF’s… Read More

#News

#Bristol Myers Squibb #Collaboration #Evotec #Neurodegenerative disorders #Neuroscience

Evotec and BMS enter drug discovery licence agreement

Evotec and Bristol Myers Squibb (BMS) have entered into an exclusive global licence agreement, extending their neuroscience partnership. The agreement covers selected late-stage discovery programmes that were developed and progressed within the collaboration between the two companies. Evotec and BMS originally entered their neurodegeneration… Read More

#News

Human brain
#AlzeCure Pharma #Antidepressants #Depression #Preclinical investigations #Psychiatry

Preclinical study proves antidepressant effects of drug

The results of a preclinical study supporting the antidepressive effects of AlzeCure Pharma’s NeuroRestore ACD856 have been published in the journal Psychopharmacology. The article focuses on new data showing that ACD856, the lead and clinical drug candidate in the NeuroRestore platform, exhibits antidepressant effects in various… Read More

#Editor's Choice #News

Neurodegenerative disorders
#Alzheimer's #Cognition Therapeutics #Interview #Neurodegenerative disorders #Neuroscience

How pharma is targeting advances in Alzheimer’s treatments

Listen to this article on the DDW Podcast: Cognition Therapeutics recently completed the enrolment of its Phase II SEQUEL trial for patients with mild-to-moderate Alzheimer’s disease. The focus of the trial is to test Cognition Therapeutics’ experimental drug, CT1812 for patients with dementia with Lewy Bodies and dry age-related macular degeneration. Read More

#Exclusive Content

Neurons
#ALS #LifeArc #MND #Motor neurone disease #University of Edinburgh

Project to test drug combinations for motor neuron disease

A new project by researchers in Edinburgh aims to identify combinations of existing drugs that could be used together to treat motor neuron disease (MND). Led by Prof Siddharthan Chandran, the £3.3 million project is funded by the medical research charity LifeArc, as part of an… Read More

#News